LIFE heads into its August 5 earnings report with its biggest shareholder selling aggressively into a stock that has surged 17% in a week.
The most striking feature of the pre-earnings setup is the insider selling pattern. GV 2019 GP LLC, a 10% owner linked to Google Ventures, has sold shares on every trading day from July 16 through July 28 — accumulating roughly $9.8 million in sales over that stretch at prices between $18.67 and $19.73. The stock has since climbed to $22.83, meaning GV was selling well below where the market now prices the shares. That consistent liquidation ahead of the print is worth watching: a major early-stage backer is reducing exposure into strength, even as the institutional picture shows new entrants. T. Rowe Price and Divisadero Street Capital both initiated positions in the second quarter, each adding over 1.5 million shares, suggesting conviction from the buy side is not uniformly fading.
The lending market has loosened dramatically alongside the price rally. Borrow availability has jumped to roughly 106% — meaning there are now more shares available to lend than are currently borrowed — a complete reversal from mid-July, when availability fell as low as 21%. Cost to borrow has dropped in parallel, from above 11% in early July to 5.8% now. Short interest has fallen 28% over the past week to around 1.35 million shares. Together these moves suggest shorts have been covering into the rally rather than adding pressure, and the borrow market is no longer stressed. The ORTEX short score has also retreated to 57.8 from a recent peak near 68, reflecting the same easing dynamic.
The analyst community is constructively positioned, though not uniformly aggressive. JP Morgan raised its target to $23 in mid-July — now fractionally below the current price — while earlier moves from Barclays and Citizens pushed targets into the mid-$20s. The consensus mean sits near $29.70, implying roughly 30% upside from current levels. Bulls point to Ethos's tech-driven underwriting platform, carrier partnerships, and revenue growth trajectory. Bears argue the capital-light, fee-based model offers limited differentiation in a competitive insurance market, and that dependence on a narrow carrier base creates concentration risk. The one prior earnings reaction on record — June 2026 — saw the stock fall 2.9% on the day and 9.1% over the following five sessions, a reminder that strong momentum has not insulated the stock from post-print weakness before.
Tomorrow's report will test whether the business fundamentals behind the recent re-rating — and the Street's optimistic target stack — can hold up against a stock that has already priced in a great deal of good news.
See the live data behind this article on ORTEX.
Open LIFE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
LIFE has staged one of the sharper rallies in its short trading history — up 77% over the past month and 17% in this week alone, closing at $21.05 on Tuesday. The tension worth watching: short sellers are rebuilding…
